1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Krebs Biochemicals & Industries Ltd.

Krebs Biochemicals & Industries Ltd.

51.85
INR
-5.63
(-9.79%)
-6.54EPS
1.30BMarket Cap
2012 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
71.82
- -
0.95
1.19
18.49
22.33
14.62
19.68
27.69
24.18
23.39
20.09
11.01
11.71
Basic EPS, GAAP
-17.7
- -
-12.06
-11.28
-12.97
-12.03
-17.9
-14.45
-20.65
-11.45
-9.15
-12.49
-7.85
-6.54
Free Cash Flow per Basic Share
3.42
- -
-19.08
-17.22
-4.5
2.34
-22.01
-7.43
-7.99
-11.46
-3.27
-5.31
-2.36
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
23.5
29.78
9.62
1.04
-12.49
-8.59
-13.89
-21.78
-34.83
-46.13
-55.29
-67.83
-75.49
- -
Tangible Book Value per Share
16.44
26.05
8.67
-1.49
-14.87
-11.02
-15.98
-23.57
-36.16
-47.38
-56.45
-68.9
-75.62
- -
Basic Weighted Avg Shares
10
10
14
14
14
17
16
20
22
22
22
22
22
22
Sales/Revenue/Turnover
708
- -
13
17
254
371
236
386
597
521
504
433
237
252
Operating Margin (%)
-15.56
- -
-1,235.49
-788.4
-49.49
-40.15
-98.84
-59.68
-66.15
-42.08
-30.14
-49.18
-33.25
-35.46
Depreciation Expense
97
- -
45
42
41
44
47
51
63
66
68
67
64
64
Net Income, GAAP
-174
- -
-163
-160
-178
-200
-289
-284
-445
-247
-197
-269
-169
-141
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-24.64
- -
-1,265.54
-946.7
-70.15
-53.89
-122.42
-73.46
-74.58
-47.36
-39.13
-62.2
-71.35
-55.85
Working Capital
-159
-162
-201
-187
-250
-239
-243
-268
-426
-330
-444
-933
-1,034
- -
LT Debt
648
176
253
740
873
910
805
1,155
1,779
2,182
2,285
2,063
2,086
- -
Total Equity
232
293
130
15
-178
-143
-250
-427
-751
-995
-1,192
-1,462
-1,628
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-54.72
- -
-77.08
-221.52
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
565
613
- -
LT Borrowings
1,650
1,636
- -
LT Finance Leases
- -
450
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
1,489
857
1,296

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
98
96
- -
Cash, Cash Equivalents & STI
2
2
- -
Accounts Receivable, Net
1
- -
- -
Inventories
58
57
- -
Total Current Liabilities
1,116
1,131
- -
Payables & Accruals
- -
- -
- -
ST Debt
565
613
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-110.42%
32.4%
11.29%
Free Cash Flow
-131.59%
-0.57%
-55.54%
Net Income, GAAP
5.59%
-1.65%
-37.14%
Sales/Revenue/Turnover
148.3%
-4.13%
-45.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
129
129
115
61
433
2026
55
42
73
68
237
2027
70
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-2.4
-2.67
-3.59
-3.83
-12.49
2026
-2.47
-2.85
-1.45
-1.09
-7.85
2027
-1.15
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Manish Kumar Jain
Full Time Employees
142
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Kothapalli (V), Kasimkota (M), Anakapalli Visakhapatnam AP India 531031
IPO Date
Mar 2, 1994
Website
krebsbiochem.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Krebs Biochemicals & Industries Limited, established in 1991 and headquartered in Visakhapatnam, India, manufactures active pharmaceutical ingredients using biotech processes encompassing chemical synthesis, fermentation, and enzymatic technologies for applications in medicine, agriculture, and industry. The company produces steroid intermediates such as androstenedione; anti-cholesterol agents including lovastatin and simvastatin; and additional APIs like amlodipine and telmisartan for anti-hypertension, cetirizine for anti-histamine, orlistat for anti-obesity, serratiopeptidase for anti-inflammatory uses, and phenylephrine for cold and cough remedies; it also provides contract manufacturing services to large pharmaceutical and multinational companies from facilities in Nellore and Visakhapatnam, Andhra Pradesh. Operations target global markets with a focus on GMP-compliant production. Promoter Ipca Laboratories Limited maintains a 49.65% stake within a stable 72.74% promoter holding as of 2025, amid ongoing financial challenges including negative equity of INR -146.24 crores, accumulated losses of INR 167.80 crores, and negative operating cash flow reported in Q2 FY26, reflecting deepening losses and liquidity constraints without recent funding rounds, acquisitions, partnerships, or major strategic shifts disclosed.